China · Delayed Price · Currency is CNY Luyan Pharma Statistics
Total Valuation
Luyan Pharma has a market cap or net worth of CNY 3.72 billion. The enterprise value is 8.39 billion.
| Market Cap | 3.72B |
| Enterprise Value | 8.39B |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Jul 10, 2026 |
Share Statistics
Luyan Pharma has 388.52 million shares outstanding. The number of shares has increased by 1.46% in one year.
| Current Share Class | 388.52M |
| Shares Outstanding | 388.52M |
| Shares Change (YoY) | +1.46% |
| Shares Change (QoQ) | +3.10% |
| Owned by Insiders (%) | 3.50% |
| Owned by Institutions (%) | 1.00% |
| Float | 232.41M |
Valuation Ratios
The trailing PE ratio is 13.68.
| PE Ratio | 13.68 |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | 12.26 |
| P/OCF Ratio | 7.66 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.97, with an EV/FCF ratio of 27.44.
| EV / Earnings | 30.84 |
| EV / Sales | 0.39 |
| EV / EBITDA | 11.97 |
| EV / EBIT | 15.13 |
| EV / FCF | 27.44 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 1.52.
| Current Ratio | 1.12 |
| Quick Ratio | 0.77 |
| Debt / Equity | 1.52 |
| Debt / EBITDA | 7.27 |
| Debt / FCF | 16.66 |
| Interest Coverage | 12.88 |
Financial Efficiency
Return on equity (ROE) is 8.09% and return on invested capital (ROIC) is 5.07%.
| Return on Equity (ROE) | 8.09% |
| Return on Assets (ROA) | 2.68% |
| Return on Invested Capital (ROIC) | 5.07% |
| Return on Capital Employed (ROCE) | 13.96% |
| Weighted Average Cost of Capital (WACC) | 2.14% |
| Revenue Per Employee | 3.77M |
| Profits Per Employee | 47,800 |
| Employee Count | 5,722 |
| Asset Turnover | 1.66 |
| Inventory Turnover | 7.09 |
Taxes
In the past 12 months, Luyan Pharma has paid 101.03 million in taxes.
| Income Tax | 101.03M |
| Effective Tax Rate | 27.36% |
Stock Price Statistics
The stock price has increased by +13.97% in the last 52 weeks. The beta is -0.01, so Luyan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | +13.97% |
| 50-Day Moving Average | 10.75 |
| 200-Day Moving Average | 13.37 |
| Relative Strength Index (RSI) | 39.68 |
| Average Volume (20 Days) | 10,439,433 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Luyan Pharma had revenue of CNY 21.57 billion and earned 273.51 million in profits. Earnings per share was 0.70.
| Revenue | 21.57B |
| Gross Profit | 1.49B |
| Operating Income | 557.50M |
| Pretax Income | 369.20M |
| Net Income | 273.51M |
| EBITDA | 633.90M |
| EBIT | 557.50M |
| Earnings Per Share (EPS) | 0.70 |
Balance Sheet
The company has 450.80 million in cash and 5.12 billion in debt, with a net cash position of -4.67 billion or -12.02 per share.
| Cash & Cash Equivalents | 450.80M |
| Total Debt | 5.12B |
| Net Cash | -4.67B |
| Net Cash Per Share | -12.02 |
| Equity (Book Value) | 3.36B |
| Book Value Per Share | 8.74 |
| Working Capital | 1.10B |
Cash Flow
In the last 12 months, operating cash flow was 492.07 million and capital expenditures -184.71 million, giving a free cash flow of 307.36 million.
| Operating Cash Flow | 492.07M |
| Capital Expenditures | -184.71M |
| Depreciation & Amortization | 76.40M |
| Net Borrowing | 61.02M |
| Free Cash Flow | 307.36M |
| FCF Per Share | 0.79 |
Margins
Gross margin is 6.91%, with operating and profit margins of 2.58% and 1.27%.
| Gross Margin | 6.91% |
| Operating Margin | 2.58% |
| Pretax Margin | 1.71% |
| Profit Margin | 1.27% |
| EBITDA Margin | 2.94% |
| EBIT Margin | 2.58% |
| FCF Margin | 1.42% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 3.65%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 3.65% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 111.59% |
| FCF Payout Ratio | 78.75% |
| Buyback Yield | -1.46% |
| Shareholder Yield | 2.19% |
| Earnings Yield | 7.31% |
| FCF Yield | 8.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2019. It was a forward split with a ratio of 1.7.
| Last Split Date | May 29, 2019 |
| Split Type | Forward |
| Split Ratio | 1.7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |